[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
1. Seidemann K, Tiemann M, Schrappe M, Yakisan E, Simonitsch I, Janka-Schaub G, Dörffel W, Zimmermann M, Mann G, Gadner H, Parwaresch R, Riehm H, Reiter A: Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood; 2001 Jun 15;97(12):3699-706
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
  • Anaplastic large-cell lymphoma (ALCL) accounts for approximately 10% of pediatric non-Hodgkin lymphoma (NHL).
  • Previous experience from NHL-Berlin-Frankfurt-Münster (BFM) trials indicated that the short-pulse B-NHL-type treatment strategy may also be efficacious for ALCL.
  • The purpose of this study was to test the efficacy of this protocol for treatment of childhood ALCL in a large prospective multicenter trial and to define risk factors.
  • Immunophenotype was T-cell in 40 patients, B-cell in 5, null in 31, and not determined in 13.
  • Extranodal manifestations were as follows: mediastinum, n = 28; lung, n = 13; skin, n = 16; soft tissue, n = 13; bone, n = 14; central nervous system, n = 1; bone marrow, n = 5.
  • After a cytoreductive prephase, treatment was stratified into 3 branches: patients in K1 (stage I and II resected) received three 5-day courses (methotrexate [MTX] 0.5 g/m(2), dexamethasone, oxazaphorins, etoposide, cytarabine, doxorubicin, and intrathecal therapy); patients in K2 (stage II nonresected and stage III) received 6 courses; patients in K3 (stage IV or multifocal bone disease) received 6 intensified courses including MTX 5 g/m(2), high-dose cytarabine/etoposide.
  • Events were as follows: progression during therapy, n = 2; progression or relapse after therapy, n = 20; second malignancy, n = 1.
  • It was concluded that short-pulse chemotherapy, stratified according to stage, is effective treatment for pediatric ALCL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Large-Cell, Anaplastic / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Germany. Humans. Immunophenotyping. Infant. Lymphoma, B-Cell / drug therapy. Male. Prospective Studies. Protein-Tyrosine Kinases / metabolism. Receptor Protein-Tyrosine Kinases. Recurrence. Risk Factors. Treatment Failure


2. Macy ME, Sawczyn KK, Garrington TP, Graham DK, Gore L: Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials. Curr Oncol Rep; 2008 Nov;10(6):477-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials.
  • The current high cure rates for children diagnosed with cancer can be attributed in part to emphasis on large cooperative group clinical trials.
  • The significant improvement in pediatric cancer survival over the past few decades is the result of optimized chemotherapy drug dosing, timing, and intensity; however, further alterations in traditional chemotherapy agents are unlikely to produce substantially better outcomes.
  • Furthermore, there remains a subset of patients who have a very poor prognosis due to tumor type or stage at presentation, or who have a dismal prognosis with relapse or recurrence.
  • As such, innovative approaches to therapy and new drugs are clearly needed for introduction into the current pediatric oncology arsenal.
  • A variety of biologically targeted therapies that have shown promise in preclinical studies and early-phase adult clinical trials are now being explored in pediatric clinical trials.
  • These novel agents hold the promise for continuing to drive forward improvements in patient survival, with potentially less toxicity than exists with traditional chemotherapy drugs.

  • MedlinePlus Health Information. consumer health - Children's Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1516-22 [17332297.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1591-600 [17332306.001]
  • [Cites] Pathol Res Pract. 2007;203(3):127-34 [17298867.001]
  • [Cites] Neural Dev. 2007;2:5 [17319963.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):347-59 [16612405.001]
  • [Cites] J Immunol. 2006 May 15;176(10):6302-12 [16670342.001]
  • [Cites] Leukemia. 2006 Jun;20(6):965-70 [16598313.001]
  • [Cites] Leukemia. 2006 Jun;20(6):952-7 [16617323.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2 Suppl 5):S36-43 [16720202.001]
  • [Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3532-40 [16740780.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4961-7 [16493003.001]
  • [Cites] Eur J Cancer. 2006 Jul;42(10):1491-500 [16759849.001]
  • [Cites] Neoplasia. 2006 May;8(5):394-401 [16790088.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3150-6 [16717292.001]
  • [Cites] Blood. 2006 Jul 15;108(2):711-7 [16822902.001]
  • [Cites] Anticancer Res. 2006 May-Jun;26(3A):1903-8 [16827123.001]
  • [Cites] Leukemia. 2006 Aug;20(8):1368-76 [16761017.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1151-7 [16614245.001]
  • [Cites] Mol Cancer Ther. 2006 Jul;5(7):1836-43 [16891470.001]
  • [Cites] Clin Lab Haematol. 2006 Aug;28(4):254-8 [16898965.001]
  • [Cites] Pediatr Blood Cancer. 2006 Sep;47(3):255-9 [16123980.001]
  • [Cites] J Natl Cancer Inst. 2006 Aug 16;98(16):1142-57 [16912267.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3904-11 [16921041.001]
  • [Cites] Pediatr Blood Cancer. 2006 Oct 15;47(5):560-6 [16395684.001]
  • [Cites] Blood. 2005 Jul 15;106(2):721-4 [15790786.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2800-8 [17363602.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1783-8 [17363533.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1789-93 [17363534.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2510-6 [17294449.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1539-44 [17442997.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1686-94 [17456774.001]
  • [Cites] Blood. 2007 May 15;109(10):4158-63 [17264294.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5151-6 [17351110.001]
  • [Cites] Blood. 2007 Jul 1;110(1):267-77 [17356134.001]
  • [Cites] Cell Biol Int. 2007 Oct;31(10):1136-43 [17493842.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(7-8):1483-8 [17350876.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5541-52 [17694093.001]
  • [Cites] Leukemia. 2007 Sep;21(9):1921-30 [17581609.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5549s-5555s [17875788.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5652s-5660s [17875803.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2286-95 [17609425.001]
  • [Cites] Clin Cancer Res. 2007 Oct 1;13(19):5834-40 [17908976.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3281-90 [17591945.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2240-5 [17657218.001]
  • [Cites] J Cell Biochem. 2004 May 1;92(1):77-91 [15095405.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5329-35 [17000665.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1372-80 [18355978.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1791-9 [16254134.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1806-9 [16291592.001]
  • [Cites] Pediatr Blood Cancer. 2006 May 1;46(5):570-8 [16365862.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jun;45(6):583-91 [16518851.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1532-42 [12176867.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11399-404 [12177446.001]
  • [Cites] Cancer. 2003 Jan 15;97(2):441-9 [12518368.001]
  • [Cites] Leuk Res. 2003 May;27(5):437-44 [12620295.001]
  • [Cites] J Pediatr Surg. 2003 Mar;38(3):308-14; discussion 308-14 [12632340.001]
  • [Cites] Blood. 2003 May 1;101(9):3597-605 [12531805.001]
  • [Cites] Int Immunopharmacol. 2003 Jun;3(6):879-87 [12781704.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3637-45 [12839953.001]
  • [Cites] N Engl J Med. 2003 Jul 31;349(5):427-34 [12890841.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1474-9 [12702504.001]
  • [Cites] Curr Opin Investig Drugs. 2003 Jun;4(6):757-63 [12901237.001]
  • [Cites] Int J Oncol. 2003 Oct;23(4):1151-7 [12963998.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2387-94 [12816873.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3982S-90S [14506197.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):436-41 [14617002.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15113-8 [14657335.001]
  • [Cites] Blood. 2004 Feb 1;103(3):784-9 [14551141.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):751-61 [14760098.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):12876-82 [14709552.001]
  • [Cites] Blood. 2000 Jan 15;95(2):639-45 [10627474.001]
  • [Cites] J Pediatr Surg. 2000 Jan;35(1):30-2; discussion 32-3 [10646769.001]
  • [Cites] Leuk Res. 2000 Mar;24(3):201-6 [10739002.001]
  • [Cites] Science. 2000 Sep 15;289(5486):1938-42 [10988075.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1527-32 [11245461.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3535-40 [11325813.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3361-9 [11369625.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1790-7 [11410521.001]
  • [Cites] Oncogene. 2000 Dec 27;19(56):6680-6 [11426655.001]
  • [Cites] Lab Invest. 2001 Jul;81(7):1025-37 [11454991.001]
  • [Cites] Mol Pathol. 2001 Aug;54(4):227-9 [11477136.001]
  • [Cites] J Clin Invest. 2001 Sep;108(6):851-9 [11560954.001]
  • [Cites] Bioconjug Chem. 2002 Jan-Feb;13(1):47-58 [11792178.001]
  • [Cites] Nat Med. 2002 Feb;8(2):128-35 [11821896.001]
  • [Cites] Mol Pathol. 2002 Feb;55(1):40-5 [11836446.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):486-92 [11914627.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Mar;133(2):105-11 [11943335.001]
  • [Cites] Blood. 2002 Jun 1;99(11):3885-91 [12010785.001]
  • [Cites] Leukemia. 2002 Jul;16(7):1302-10 [12094254.001]
  • [Cites] Cancer Cell. 2002 Jun;1(5):433-43 [12124173.001]
  • [Cites] Mol Immunol. 2007 Feb;44(6):1331-41 [16814387.001]
  • [Cites] Klin Padiatr. 2006 Nov-Dec;218(6):327-33 [17080335.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3504-13 [16840725.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3271-9 [16882711.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4354-62 [15781881.001]
  • [Cites] Cancer Lett. 2005 Oct 18;228(1-2):37-41 [15923079.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1536-42 [16015387.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):407-19 [16286248.001]
  • [Cites] Oncology. 2005;69 Suppl 3:46-56 [16301835.001]
  • [Cites] Curr Mol Med. 2005 Nov;5(7):653-61 [16305491.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4253-60 [16131572.001]
  • [Cites] Eur J Haematol. 2006 Jan;76(1):23-32 [16343268.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):112-9 [16323176.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):473-81 [16397263.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1149-55 [16195324.001]
  • [Cites] Cell. 2006 Feb 10;124(3):471-84 [16469695.001]
  • [Cites] Curr Med Chem. 2006;13(26):3165-89 [17168705.001]
  • [Cites] Cancer Lett. 2007 Mar 8;247(1):84-90 [16730884.001]
  • [Cites] Exp Hematol. 2007 Feb;35(2):263-73 [17258075.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1155-62 [17283150.001]
  • [Cites] Leuk Lymphoma. 2002 May;43(5):1007-11 [12148879.001]
  • [Cites] Blood. 2004 May 1;103(9):3544-6 [14670924.001]
  • [Cites] Blood. 2004 May 15;103(10):3669-76 [14726387.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):335-48 [15122205.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3645-52 [15150124.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3371-6 [15161691.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):470-80 [15170449.001]
  • [Cites] Cancer Invest. 2004;22(2):304-11 [15199612.001]
  • [Cites] Semin Cancer Biol. 2004 Oct;14(5):365-73 [15288262.001]
  • [Cites] Leuk Lymphoma. 2004 Jun;45(6):1185-90 [15359999.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7099-109 [15466206.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Bone Marrow Transplant. 2004 Nov;34(9):799-806 [15361903.001]
  • [Cites] Blood. 1992 Nov 15;80(10):2584-93 [1384791.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8324-8 [8078881.001]
  • [Cites] Int J Cancer. 1994 Sep 15;58(6):793-8 [7523310.001]
  • [Cites] Mol Cell Biol. 1995 Jul;15(7):3516-22 [7791758.001]
  • [Cites] J Med Chem. 1995 Sep 15;38(19):3806-12 [7562911.001]
  • [Cites] Leukemia. 1996 Jun;10(6):957-63 [8667652.001]
  • [Cites] Mol Endocrinol. 1996 Jun;10(6):705-12 [8776730.001]
  • [Cites] Mol Cell Biol. 1996 Oct;16(10):5839-45 [8816498.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4570-4 [8840962.001]
  • [Cites] Am J Pathol. 1997 Mar;150(3):815-21 [9060819.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2687-93 [9205078.001]
  • [Cites] Leuk Lymphoma. 1997 Jun;26(1-2):57-65 [9250788.001]
  • [Cites] Blood. 1997 Sep 1;90(5):2020-6 [9292538.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):3881-5 [9307264.001]
  • [Cites] Oncogene. 1997 Nov 6;15(19):2333-42 [9393877.001]
  • [Cites] Annu Rev Cell Dev Biol. 1997;13:513-609 [9442882.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1700-5 [9473236.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4426-33 [9766674.001]
  • [Cites] Science. 1999 Apr 30;284(5415):770-6 [10221902.001]
  • [Cites] Am J Med Genet. 1999 Mar 26;89(1):14-22 [10469432.001]
  • [Cites] Int J Cancer. 2005 Jan 10;113(2):179-88 [15455381.001]
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23):4804-9 [15570082.001]
  • [Cites] Blood. 2005 Jan 15;105(2):812-20 [15374878.001]
  • [Cites] Blood. 2005 Feb 1;105(3):986-93 [15459012.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):380-9 [15671569.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2406-11 [15781656.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2544-55 [15753462.001]
  • [Cites] Curr Drug Targets. 2005 May;6(3):243-57 [15857286.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3396-403 [15908652.001]
  • [Cites] Eur J Haematol. 2005 Jul;75(1):41-6 [15946309.001]
  • [Cites] Blood. 2005 Jul 1;106(1):318-27 [15784732.001]
  • [Cites] Oncogene. 2007 Nov 8;26(51):7185-93 [17525741.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jan;50(1):37-45 [17420992.001]
  • [Cites] Pediatr Blood Cancer. 2008 Feb;50(2):254-8 [17262795.001]
  • [Cites] Pediatr Blood Cancer. 2008 Feb;50(2):213-7 [17941064.001]
  • [Cites] Natl Vital Stat Rep. 2007 Nov 20;56(5):1-95 [18092547.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20558-63 [18077357.001]
  • [Cites] Pediatr Blood Cancer. 2008 Mar;50(3):581-7 [17457854.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1654-64 [18006697.001]
  • [Cites] Mol Cancer Ther. 2008 Feb;7(2):418-24 [18245671.001]
  • [Cites] J Med Chem. 2008 Feb 28;51(4):1068-72 [18247547.001]
  • [Cites] Pediatr Blood Cancer. 2008 Apr;50(4):799-805 [17635004.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2765-75 [18057228.001]
  • [Cites] Leuk Res. 2008 Jun;32(6):893-903 [18179820.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jun;50(6):1198-206 [17914733.001]
  • [Cites] J Clin Oncol. 2008 Apr 10;26(11):1810-6 [18347007.001]
  • [Cites] Oncogene. 2008 May 1;27(20):2910-22 [18026138.001]
  • [Cites] FASEB J. 2008 May;22(5):1560-71 [18171692.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jul;51(1):34-41 [18260120.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jul;51(1):42-8 [18293383.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):2962-9 [18483362.001]
  • (PMID = 18928662.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA082086-09; United States / NCI NIH HHS / CA / T32 CA082086; United States / NCI NIH HHS / CA / T32 CA082086-09
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, IGF Type 1
  • [Number-of-references] 140
  • [Other-IDs] NLM/ NIHMS308021; NLM/ PMC3309527
  •  go-up   go-down


3. Sandlund JT, Santana VM, Hudson MM, Onciu M, Head D, Murry DJ, Ribeiro R, Wallace D, Rencher R, Pui CH: Combination of dexamethasone, high-dose cytarabine, and carboplatin is effective for advanced large-cell non-Hodgkin lymphoma of childhood. Cancer; 2008 Aug 15;113(4):782-90
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of dexamethasone, high-dose cytarabine, and carboplatin is effective for advanced large-cell non-Hodgkin lymphoma of childhood.
  • BACKGROUND: The purpose of the current study was to evaluate the activity and toxicity of dexamethasone, high-dose cytarabine, and carboplatin (DAC) combination therapy in children with newly diagnosed large-cell non-Hodgkin lymphoma (NHL) and to estimate the event-free and overall survival rates achieved when DAC is incorporated into a conventional regimen.
  • METHODS: From 1991 to 1997, 20 boys and 5 girls aged 4.2 to 17.7 years who had stage III (according to the St. Jude staging system) (n = 21) or stage IV (n = 4) large-cell NHL were treated in this study.
  • DAC therapy was administered at the beginning of the induction phase in 2 sequential cycles and incorporated throughout a continuation phase (modified from the ACOP+ regimen, which features doxorubicin, cyclophosphamide, vincristine, and prednisone) with doxorubicin, cyclophosphamide, vincristine, and dexamethasone.
  • The total duration of treatment was approximately 10 months.
  • RESULTS: DAC therapy yielded a response in 22 of 25 patients (88%; 95% confidence interval [95% CI], 68%-97%): complete remission in 13 cases (52%), and partial response in 9 (36%).
  • After additional treatment with doxorubicin, cyclophosphamide, vincristine, and dexamethasone, complete remission was attained in 18 patients (72%) and partial remission in 3 (12%).
  • The event-free survival rate (+/- the standard error [SE]) was 64% +/- 9% and the overall survival rate was 80% +/- 8% at 5 years.
  • CONCLUSIONS: The results of the current study indicate that the DAC regimen is well tolerated and effective for pediatric patients with large-cell NHL.


Advertisement
4. Rosolen A, Pillon M, Garaventa A, Burnelli R, d'Amore ES, Giuliano M, Comis M, Cesaro S, Tettoni K, Moleti ML, Tamaro P, Visintin G, Zanesco L: Anaplastic large cell lymphoma treated with a leukemia-like therapy: report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 protocol. Cancer; 2005 Nov 15;104(10):2133-40
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphoma treated with a leukemia-like therapy: report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 protocol.
  • BACKGROUND: Childhood anaplastic large cell lymphoma (ALCL) is a well defined entity with a rather poor prognosis.
  • Different approaches have been adopted in the treatment of ALCL in various cooperative trials, including short high-dose intensive therapy and leukemia-like protocols.
  • In the early 1990s, the Italian Association of Pediatric Hematology and Oncology (AIEOP) initiated a multicenter trial for the treatment of ALCL based on a modified LSA2-L2 protocol.
  • Treatment was comprised of an induction of remission phase, followed by consolidation and maintenance for a total duration of 24 months, independently of disease stage.
  • Therapy was well tolerated and hematologic toxicity was the most frequent toxicity.
  • CONCLUSIONS: The leukemia-like protocol AIEOP LNH-92 was found to be an effective treatment for childhood ALCL.
  • Its long duration may be beneficial to specific patient subgroups, but optimal treatment duration in ALCL remains to be elucidated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / mortality
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cyclophosphamide / therapeutic use. Daunorubicin / therapeutic use. Disease-Free Survival. Female. Humans. Immunohistochemistry. Leukemia / therapy. Male. Methotrexate / therapeutic use. Neoplasm Staging. Prednisone / therapeutic use. Survival Analysis. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society
  • (PMID = 16211546.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; LSA2-L2 protocol
  •  go-up   go-down


5. Guerra J, Echevarria-Escudero M, Barrio N, Velez-Rosario R: Primary endobronchial anaplastic large cell lymphoma in a pediatric patient. P R Health Sci J; 2006 Jun;25(2):159-61
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary endobronchial anaplastic large cell lymphoma in a pediatric patient.
  • The authors describe a pediatric patient who presented with a 3-month history of dry cough, chest pain, progressive breathlessness, fever and recurrent pneumonia with atelectasis.
  • A biopsy of the lesion demonstrated an anaplastic large cell lymphoma (ALCL).
  • After the patient completed chemotherapy the lesion abated and she has been in complete remission for almost 4 years.
  • Although extranodal involvement of ALCL is frequent at some stage of the disease, endobronchial involvement is extremely rare even in the presence of advanced disease.
  • To our knowledge, this is the first primary isolated endobronchial ALCL described in a pediatric patient.
  • [MeSH-major] Bronchial Neoplasms. Lymphoma, Large B-Cell, Diffuse
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / therapeutic use. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Bronchi / pathology. Bronchoscopy. Child. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Immunosuppressive Agents / administration & dosage. Immunosuppressive Agents / therapeutic use. Injections, Intravenous. Injections, Spinal. Methotrexate / administration & dosage. Methotrexate / therapeutic use. Prednisone / administration & dosage. Radiography, Thoracic. Remission Induction. Tomography, Emission-Computed, Single-Photon. Tomography, X-Ray Computed. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203715.001).
  • [ISSN] 0738-0658
  • [Journal-full-title] Puerto Rico health sciences journal
  • [ISO-abbreviation] P R Health Sci J
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Puerto Rico
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 0 / Immunosuppressive Agents; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


6. Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, Weston C, Raphael M, Perkins SL, McCarthy K, Cairo MS, FAB/LMB96 International Study Committee: Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood; 2007 Apr 1;109(7):2773-80
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients.
  • A previous study (LMB89) of the French Society of Pediatric Oncology for childhood mature B-cell lymphoma (B-NHL) demonstrated a 92% 3-year event-free survival (EFS) for intermediate-risk group B defined as "non-resected" stage II/I and CNS-negative advanced-stage IIV/IV (70% of cases).
  • We performed the FAB/LMB96 trial to assess the possibility of reducing treatment in children/adolescents with intermediate-risk B-NHL without jeopardizing survival.
  • The analysis showed no significant effect of any of the treatment reductions on EFS and survival.
  • There was no interaction between the 2 treatment reductions or between each treatment reduction and LDH level or histologic subtypes (Burkitt/Burkitt-like or large B-cell).
  • Children/adolescents with intermediate-risk B-NHL who have an early response and achieve a complete remission after the first consolidation course can be cured with a 4-course treatment with a total dose of only 3.3 g/m2 cyclophosphamide and 120 mg/m2 doxorubicin.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Burkitt Lymphoma / drug therapy. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Male. Methotrexate / administration & dosage. Prednisone / administration & dosage. Remission Induction. Risk Factors. Survival Rate. Time Factors. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pediatr Hematol Oncol. 1991 Fall;13(3):288-95 [1793154.001]
  • [Cites] Blood. 2006 May 15;107(10):4047-52 [16424389.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):925-34 [8622041.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]
  • [Cites] Br J Cancer. 2000 Apr;82(8):1396-402 [10780517.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):414-9 [11208833.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):441-8 [11786572.001]
  • [Cites] Leukemia. 2002 Apr;16(4):594-600 [11960338.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2783-8 [12065554.001]
  • [Cites] Br J Haematol. 2003 Feb;120(4):660-70 [12588354.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):385-94 [15241838.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Sep;26(9):555-60 [15342981.001]
  • [Cites] Semin Oncol. 1980 Sep;7(3):332-9 [7414342.001]
  • [Cites] J Chronic Dis. 1981;34(9-10):469-79 [7276137.001]
  • [Cites] J Chronic Dis. 1985;38(8):683-90 [4019705.001]
  • [Cites] J Clin Oncol. 1986 Aug;4(8):1219-26 [3525767.001]
  • [Cites] J Clin Oncol. 1989 Mar;7(3):304-9 [2493074.001]
  • [Cites] Stat Med. 1989 Oct;8(10):1191-8 [2814068.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):123-32 [1985161.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1252-61 [8648381.001]
  • [Cites] Med Pediatr Oncol. 1997 Dec;29(6):526-33 [9324339.001]
  • [Cites] Br J Cancer. 1998 Jun;77(12):2281-5 [9649146.001]
  • [Cites] Blood. 2005 Feb 1;105(3):948-58 [15486066.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):359-72 [7844597.001]
  • (PMID = 17132719.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; MEVAP protocol
  • [Other-IDs] NLM/ PMC1852229
  •  go-up   go-down


7. Bubała H, Małdyk J, Włodarska I, Sońta-Jakimczyk D, Szczepański T: ALK-positive diffuse large B-cell lymphoma. Pediatr Blood Cancer; 2006 May 1;46(5):649-53
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-positive diffuse large B-cell lymphoma.
  • Anaplastic lymphoma kinase (ALK) positive diffuse large B-cell lymphoma (DLBCL) is a rare subtype of non-Hodgkins lymphoma.
  • The disease in this patient was highly resistant to applied chemotherapy regimens and to radiotherapy.
  • Analysis of the disease course in our patient and review of other cases reported previously show that ALK + DLBCL can be an aggressive malignancy that can be cured with conventional chemotherapy protocols only at stage of localized disease.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Protein-Tyrosine Kinases / metabolism
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Child. Humans. In Situ Hybridization, Fluorescence. Male. Receptor Protein-Tyrosine Kinases

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15852431.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


8. Gupta D, Sharma A, Raina V, Bakhshi S, Mohanti BK: Primary testicular non-Hodgkin lymphoma: a single institution experience from India. Indian J Cancer; 2009 Jan-Mar;46(1):46-9
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary testicular non-Hodgkin lymphoma: a single institution experience from India.
  • BACKGROUND: Primary testicular non-Hodgkin lymphoma (NHL) is an uncommon extra nodal presentation, constituting 1% of all NHL.
  • Median age at time of presentation is 60 years.
  • These six cases were analyzed for baseline clinical features, investigations, staging, treatment and outcome variables.
  • Five patients (83%) had stage IV and one had stage IE disease.
  • Majority had diffuse large B-cell histology (83%).
  • All patients were treated with anthracycline based combination chemotherapy and CNS prophylaxis after local therapy except one pediatric patient who did not receive any local therapy.
  • Four patients completed therapy and are on follow up while two patients having extensive disease with poor performance status died of neutropenic sepsis after 1-2 cycles of chemotherapy.
  • CONCLUSION: Primary testicular NHL is an uncommon entity and with current combined modality treatment and CNS prophylaxis, the outcome may be as good as nodal NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19282566.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


9. Laver JH, Mahmoud H, Pick TE, Hutchison RE, Weinstein HJ, Schwenn M, Weitzman S, Murphy SB, Ochoa S, Shuster JJ: Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non-Hodgkin's lymphoma: a Pediatric Oncology Group study. Leuk Lymphoma; 2002 Jan;43(1):105-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non-Hodgkin's lymphoma: a Pediatric Oncology Group study.
  • PURPOSE: The Pediatric Oncology Group (POG) adopted a histology-based approach to the management of pediatric non-Hodgkin's lymphomas (NHL) utilizing the National Cancer Institute Working Formulation for Clinical Usage.
  • Patients with diffuse large cell lymphoma (DLCL) were treated on a separate protocol from small cell diffuse undifferentiated or lymphoblastic lymphomas.
  • PATIENTS AND METHODS: One hundred and twenty eligible stage III or IV NHL patients with the confirmed diagnosis of diffuse large cell or immunoblastic histology were enrolled on study between October 1986 and November 1991.
  • In both treatment programs methotrexate was substituted when the doxorubicin cumulative dose reached 450 mg/m2.
  • Radiation was administered to bulky disease if progression or no response were observed after induction therapy.
  • Planned duration of therapy was 12 months.
  • While there was no statistically significant difference between the two treatment arms (p = 0.28), we can only say that we are 95% confident that the difference in 5-year EFS falls in the wide range from 28% in favor of APO to 8% favoring ACOP+.
  • Ten patients received radiation therapy to achieve remission.
  • CONCLUSION: The efficacy of elimination of cyclophosphamide from the treatment program of children and adolescents with advanced stage diffuse large cell lymphoma was inconclusive as to its effect on EFS.
  • Furthermore, the majority of the patients (92%) did not require any radiation therapy to bulky disease indicating that the chemotherapy regimens are quite efficient for achievement of complete remission.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Adolescent. Child. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Male. Prednisone / administration & dosage. Prospective Studies. Recurrence. Remission Induction / methods. Survival Rate. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11908712.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA03161; United States / NCI NIH HHS / CA / CA05587; United States / NCI NIH HHS / CA / CA11233; United States / NCI NIH HHS / CA / CA15089; United States / NCI NIH HHS / CA / CA20549; United States / NCI NIH HHS / CA / CA25408; United States / NCI NIH HHS / CA / CA28383; United States / NCI NIH HHS / CA / CA28476; United States / NCI NIH HHS / CA / CA29139; United States / NCI NIH HHS / CA / CA30696; United States / NCI NIH HHS / CA / CA32053; United States / NCI NIH HHS / CA / CA33603; United States / NCI NIH HHS / CA / CA35587; United States / NCI NIH HHS / CA / CA69177; United States / NCI NIH HHS / CA / CA69428
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone; ACOP protocol 2
  •  go-up   go-down


10. Laver JH, Mahmoud H, Pick TE, Hutchinson RE, Weinstein HJ, Schwenn M, Weitzman S, Murphy SB, Ochoa S, Shuster JJ, Pediatric Oncology Group: Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non Hodgkin's lymphoma: a Pediatric Oncology Group study. Leuk Lymphoma; 2001 Jul;42(3):399-405
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non Hodgkin's lymphoma: a Pediatric Oncology Group study.
  • The Pediatric Oncology Group (POG) adopted a histology-based approach to the management of pediatric non-Hodgkin's lymphomas (NHL) utilizing the National Cancer Institute Working Formulation for Clinical Usage.
  • Patients with diffuse large cell lymphoma (DLCL) were treated on a separate protocol from small cell diffuse undifferentiated or lymphoblastic lymphomas.
  • One hundred and twenty eligible stage III or IV NHL patients with the confirmed diagnosis of diffuse large cell or immunoblastic histology were enrolled on study between October 1986 and November 1991.
  • In both treatment programs methotrexate was substituted when the doxorubicin cumulative dose reached 450 mg/m2.
  • Radiation was administered to bulky disease if progression or no response were observed after induction therapy.
  • Planned duration of therapy was 12 months.
  • While there was no statistically significant difference between the two treatment arms (p = 0.28), we can only say that we are 95% confident that the difference in 5-year EFS falls in the wide range from 28% in favor of APO to 8% favoring ACOP+.
  • Ten patients received radiation therapy to achieve.
  • In conclusion the efficacy of elimination of cyclophosphamide from the treatment program of children and adolescents with advanced stage diffuse large cell lymphoma was inconclusive as to its effect on EFS.
  • Furthermore, the majority of the patients (92%) did not require any radiation therapy to bulky disease indicating that the chemotherapy regimens are quite efficient for achievement of complete remission.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adolescent. Antigens, CD / analysis. Child. Continental Population Groups. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Humans. Immunohistochemistry. Neoplasm Metastasis. Prednisolone / administration & dosage. Prednisone / administration & dosage. Remission Induction. Time Factors. United States. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11699405.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VB0R961HZT / Prednisone; VAP-cyclo protocol; VPD protocol
  •  go-up   go-down


11. Márky I, Björk O, Forestier E, Jónsson OG, Perkkiö M, Schmiegelow K, Storm-Mathiesen I, Gustafsson G, Nordic Society of Pediatric Hematology and Oncology: Intensive chemotherapy without radiotherapy gives more than 85% event-free survival for non-Hodgkin lymphoma without central nervous involvement: a 6-year population-based study from the nordic society of pediatric hematology and oncology. J Pediatr Hematol Oncol; 2004 Sep;26(9):555-60
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemotherapy without radiotherapy gives more than 85% event-free survival for non-Hodgkin lymphoma without central nervous involvement: a 6-year population-based study from the nordic society of pediatric hematology and oncology.
  • BACKGROUND: The prognosis in childhood non-Hodgkin lymphoma (NHL) has improved dramatically during recent decades.
  • The authors report the results from a 6-year population-based study of clinical characteristics and treatment results of NHL from the five Nordic countries.
  • METHODS: All children younger than 15 years of age at diagnosis with NHL diagnosed from 1995 to 2000 were stratified and treated according to immunophenotypic classification and stage of disease.
  • Patients with pre-B and T-cell NHL constituted 33%, B-cell NHL 53%, and anaplastic large cell lymphoma (ALCL) 14%.
  • According to Murphy's classification, 14% had stage 1, 17% stage 2, 50% stage 3, and 19% stage 4 disease, 12 of whom (28%) had central nervous involvement (CNS) at diagnosis.
  • The 5-year p-EFS values were 91% for B-cell, 87% for pre-B, 81% for ALCL, and 79% for T-cell NHL.
  • The 12 patients with CNS involvement at diagnosis had a significantly poorer outcome than stage 4 patients with CNS involvement (p-EFS = 50% vs. 90%, P < 0.01).
  • CONCLUSIONS: With modern intensive chemotherapy, more than 85% of NHL patients will achieve long-lasting first remission.
  • In the future, preventing death during induction and remission and improving therapy for patients with CNS disease would have a major impact on the overall p-EFS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Finland / epidemiology. Humans. Iceland / epidemiology. Immunophenotyping. Incidence. Male. Neoplasm Staging. Remission Induction. Scandinavian and Nordic Countries / epidemiology. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15342981.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Seidemann K, Tiemann M, Lauterbach I, Mann G, Simonitsch I, Stankewitz K, Schrappe M, Zimmermann M, Niemeyer C, Parwaresch R, Riehm H, Reiter A, NHL Berlin-Frankfurt-Münster Group: Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt-Münster Group. J Clin Oncol; 2003 May 1;21(9):1782-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt-Münster Group.
  • PURPOSE: Primary mediastinal large B-cell lymphoma with sclerosis (PMLBL) is a rare entity of non-Hodgkin's lymphoma (NHL) arising from thymic mature B cells.
  • Optimal treatment strategies remain to be established, especially in pediatric patients.
  • PATIENTS AND METHODS: This study analyzes clinical characteristics and treatment outcome of 30 pediatric patients with PMLBL, diagnosed in multicenter therapy NHL-Berlin-Frankfurt-Münster Group (BFM) trials.
  • Treatment was stratified by stage and serum lactate dehydrogenase (LDH) and consisted of four to six 5-day courses of chemotherapy using steroids, oxazaphosphorine alkylating agents, methotrexate, cytarabine, etoposide, and doxorubicin.
  • With a median observation time of 5 years (range, 1 to 12 years), probability of event-free survival (pEFS) at 5 years was 0.70 (SE, 0.08).
  • Two patients erroneously diagnosed as T-cell NHL received non-B-cell therapy and died from progress of disease.
  • Events in 28 patients receiving B-cell therapy included early progress during therapy (n = 1) and relapse (n = 6).
  • Residual mediastinal masses were present in 23 patients after two courses of therapy and in 15 patients after the end of therapy.
  • Dose-intense chemotherapy including high-dose methotrexate yields a pEFS at 5 years of 0.70 (SE, 0.08).
  • LDH is of prognostic value in pediatric patients with PMLBL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adolescent. Adrenal Cortex Hormones / therapeutic use. Antineoplastic Agents, Alkylating / administration & dosage. Child. Child, Preschool. Cytarabine / administration & dosage. Disease Progression. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Infant. L-Lactate Dehydrogenase / analysis. Male. Methotrexate / administration & dosage. Prognosis. Sclerosis / etiology. Sclerosis / pathology. Treatment Outcome

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12721255.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antineoplastic Agents, Alkylating; 0 / Biomarkers, Tumor; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; EC 1.1.1.27 / L-Lactate Dehydrogenase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


13. Laver JH, Kraveka JM, Hutchison RE, Chang M, Kepner J, Schwenn M, Tarbell N, Desai S, Weitzman S, Weinstein HJ, Murphy SB: Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol; 2005 Jan 20;23(3):541-7
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial.
  • PURPOSE: The Pediatric Oncology Group adopted a histology-based approach to non-Hodgkin's lymphoma and treated patients with advanced large-cell lymphoma on a separate protocol (doxorubicin, vincristine, prednisone, 6-mercaptopurin, and methotrexate; APO regimen).
  • In this study, we assessed the effects of an intense antimetabolite therapy alternating with APO on overall survival (OS) and event-free survival (EFS) and looked into biologic correlates.
  • PATIENTS AND METHODS: From December 1994 to April 2000, we enrolled 180 eligible pediatric patients with stage III/IV large-cell lymphoma (LCL); 90 patients were randomly assigned to the intermediate-dose methotrexate (IDM) and high-dose cytarabine (HiDAC) arm, 85 patients to the APO arm, and five patients directly to the APO arm by study design due to CNS involvement.
  • Planned therapy duration was 12 months.
  • RESULTS: The 4-year EFS for all patients was 67.4% (SE, 4.2%), and OS was 80.1% (SE, 3.6%) without any significant difference between the two arms.
  • The 4-year EFS and OS were 71.8% (SE, 6.1%) and 88.1% (SE, 4.4%), respectively, for patients with anaplastic large-cell lymphoma, and 63.8% (SE, 10.3%) and 70.3% (SE, 9.0%), respectively, for patients with diffuse large B-cell lymphoma.
  • CONCLUSION: The efficacy of incorporating IDM/HiDAC in the treatment plan of pediatric and adolescent patients with advanced-stage LCL was inconclusive as to its effect on EFS, regardless of the lymphoma phenotype.
  • It cannot be excluded that with a higher number of patients, one treatment could prove superior and future studies will build on these data.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / secondary. Lymphoma, Large B-Cell, Diffuse / drug therapy. Neoplasm Staging
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Adolescent. Adult. Age Factors. Child. Child, Preschool. Cytarabine / administration & dosage. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Female. Humans. Infant. Infusions, Intravenous. Injections, Spinal. Male. Methotrexate / administration & dosage. Prednisone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15659500.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; APO combination
  •  go-up   go-down


14. Forns M, Javier G, Estella J, Fernández-Delgado R, Gallego S, García-Miguel P, Indiano JM, Navajas A, Pardo N, en representación del grupo SHOP de las Sociedades Españolas de Hematología (SEHP) y Oncología Pediátricas (SEOP): [Results of the SHOP LNHB98 (LMB89) trial in pediatric patients with B-cell non-Hodgkin's lymphoma]. Med Clin (Barc); 2007 May 5;128(17):641-6
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of the SHOP LNHB98 (LMB89) trial in pediatric patients with B-cell non-Hodgkin's lymphoma].
  • BACKGROUND AND OBJECTIVE: After the good results obtained by the Société Française d'Oncologie Pédiatrique (SFOP) regarding the pediatric B-type non-Hodgkin's (Burkitt and large B-cell) lymphoma and L3 leukemia, the Sociedad Española de Hematología y Oncología Pediátricas (SHOP) decided to use the same treatment protocol.
  • PATIENTS AND METHOD: Pediatric patients diagnosed with B-type non-Hodgkin's lymphoma without a previous history of malignant diseases were eligible for this study.
  • They were classified in 3 groups of risk: group A (resected stage I and abdominal stage II), group B (not eligible for groups A or C), and group C (with central nervous system involvement and L3 leukemia).
  • All received treatment according to the SFOP's LMB89 protocol.
  • CONCLUSIONS: The results confirm the good efficiency of the LMB89 protocol for treating B-cell lymphoma and L3 leukemia, despite having diminished the treatment intensity in the less risk groups.
  • In addition, no differences were evidenced between Burkitt and large B-cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Humans. Hydrocortisone / therapeutic use. Infant. Leucovorin / therapeutic use. Male. Methotrexate / therapeutic use. Prednisone / therapeutic use. Prospective Studies. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17537360.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Spain
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate; LMB89 protocol
  •  go-up   go-down


15. Massimino M, Spreafico F, Luksch R, Giardini R: Prognostic significance of p80 and visceral involvement in childhood CD30 anaplastic large cell lymphoma (ALCL). Med Pediatr Oncol; 2001 Aug;37(2):97-102
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of p80 and visceral involvement in childhood CD30 anaplastic large cell lymphoma (ALCL).
  • BACKGROUND: Between 1976 and 1998, CD30+anaplastic large cell lymphoma (ALCL) was diagnosed in 44 children (28 males, 16 females, age range 2.7-16.1 years, median 10).
  • Up to 1993, 32 such children were treated according to a common chemotherapeutic protocol that stratified patients according to stage, without considering presenting features.
  • Thereafter, patients presenting with visceral (lung, spleen, liver, gastro-intestinal tract) or mediastinal involvement were assigned to a high-risk treatment protocol with induction intensification.
  • The generation of these two risk-groups was the result of a retrospective analysis of clinical risk factors for therapy failure as previously reported [Massimino M, Gasparini M, Giardini R, Ann Oncol 1995;6:915-920].
  • PROCEDURE: We tested 15/21 cases of group A, and 18/22 of group B for p80 immunoreactivity in order to investigate a possible correlation between ALCL locations and NPM-ALK expression.
  • CONCLUSIONS: It is impossible to conclude anything about p80 positivity based on a series of 33/44 patients with childhood ALCL, neither about over-all prognosis nor about the role of visceral involvement.
  • [MeSH-major] Antigens, CD30 / immunology. Lymphoma, Large B-Cell, Diffuse / drug therapy. Neoplasm Metastasis. Protein-Tyrosine Kinases / biosynthesis
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Gene Expression Regulation, Neoplastic. Humans. Immunoassay. Infant. Male. Prognosis. Retrospective Studies. Risk Factors. Treatment Outcome. Viscera / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11496346.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; EC 2.7.1.- / p80(NPM-ALK) protein; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


16. Seidemann K, Henze G, Beck JD, Sauerbrey A, Kühl J, Mann G, Reiter A: Non-Hodgkin's lymphoma in pediatric patients with chromosomal breakage syndromes (AT and NBS): experience from the BFM trials. Ann Oncol; 2000;11 Suppl 1:141-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma in pediatric patients with chromosomal breakage syndromes (AT and NBS): experience from the BFM trials.
  • BACKGROUND: Lymphoma and leukemia are the commonest malignant diseases in patients with chromosomal breakage syndromes and immunodeficiency (Ataxia teleangiectasia (AT) and Nijmegen breakage syndrome (NBS)).
  • With improved management of infections, malignant disease is more frequently diagnosed and has become one of the commonest causes of death in pediatric AT and NBS.
  • PATIENTS AND METHODS: In three consecutive multicenter therapy trials for pediatric non-Hodgkin's lymphoma (NHL) (NHL-BFM), 1569 patients with newly diagnosed NHL have been registered between 1986 and 1997.
  • NHL-entities differed from non-AT/NBS-patients: diffuse large B-cell lymphomas, n = 7 (78%); ALCL, n = 1; lymphoblastic T-cell lymphoma, n = 1.
  • All patients received polychemotherapy according to tumor-entity and stage, none received radiation.
  • CONCLUSIONS: Patients with AT and NBS suffer from rare entities of pediatric NHL.
  • Curative treatment is possible and should be attempted.
  • Intensity of therapy should be adjusted to individual risk factors and tolerance.

  • MedlinePlus Health Information. consumer health - Ataxia Telangiectasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10707797.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


17. Mora J, Filippa DA, Thaler HT, Polyak T, Cranor ML, Wollner N: Large cell non-Hodgkin lymphoma of childhood: Analysis of 78 consecutive patients enrolled in 2 consecutive protocols at the Memorial Sloan-Kettering Cancer Center. Cancer; 2000 Jan 1;88(1):186-97
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large cell non-Hodgkin lymphoma of childhood: Analysis of 78 consecutive patients enrolled in 2 consecutive protocols at the Memorial Sloan-Kettering Cancer Center.
  • BACKGROUND: The authors report a study of pediatric patients with advanced diffuse large cell lymphoma (DLCL) who were treated with 2 consecutive regimens, LSA2-L2 and LSA4, over a 25-year-period at the Memorial Sloan-Kettering Cancer Center.
  • They also describe a comparative analysis of two subgroups retrospectively identified as having CD30 positive (+) anaplastic large cell lymphoma (ALCL) and CD30 negative (-) DLCL.
  • To the authors' knowledge, this study represents the longest follow-up on the largest series of uniformly treated pediatric DLCL patients reported to date.
  • METHODS: A total of 78 consecutive patients were treated for Stage III/IV DLCL.
  • RESULTS: A disease free survival rate of 72% in patients with advanced stage DLCL using the LSA2-L2 and LSA4 regimens.
  • Of 52 patients for whom immunophenotypic data were available, 28 had disease of B-cell lineage, 24 had disease of T-cell/null phenotype, 19 were CD30+ (36.
  • 5%), 18 had disease of T-cell phenotype, and 1 had disease of B-cell lineage.
  • CONCLUSIONS: The CD30- DLCL cases mostly were of B-cell lineage, had a small risk of treatment failure, and did not develop a recurrence off therapy.
  • A distinct clinical pattern was identified for the CD30+ ALCL group; although these tumors were of T-cell lineage and had a significantly higher rate of late recurrences (median follow-up of 24 months) they all were salvageable.
  • Based on the findings of the current study, the authors propose that T-cell CD30+ ALCL be addressed in the future according to equal dose intensity regimens in induction therapy, as is done for B-cell lymphomas; prolonged periods of maintenance chemotherapy, as is done for T-cell lymphoblastic lymphomas; and no central nervous system prophylaxis beyond the induction period unless other recognized risk factors are present.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor. Child. Child, Preschool. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Incidence. Infant. Male. Neoplasm Staging. Neoplasms, Second Primary / complications. Retrospective Studies. Treatment Outcome


18. Gore L, Trippett TM: Emerging non-transplant-based strategies in treating pediatric non-Hodgkin's lymphoma. Curr Hematol Malig Rep; 2010 Oct;5(4):177-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emerging non-transplant-based strategies in treating pediatric non-Hodgkin's lymphoma.
  • Although intensive multi-agent chemotherapy has made non-Hodgkin's lymphoma one of the most curable malignancies in children and young adults, there is room for improvement in treatment, particularly for those with advanced-stage disease and those who relapse after conventional therapy.
  • New approaches are now attempting to reduce the burden of treatment, to focus on novel and more specific biologic targets, and to improve outcomes for patients with advanced-stage disease while reducing the potential for late effects.
  • A comprehensive review of all potential agents is beyond the scope of this review, which will focus on some of the newer strategies for treating non-Hodgkin's lymphoma that are coming into clinical use today.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / therapeutic use. Burkitt Lymphoma / pathology. Burkitt Lymphoma / therapy. Child. Cysteine Proteinase Inhibitors / therapeutic use. Histone Deacetylase Inhibitors / therapeutic use. Humans. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, Large-Cell, Anaplastic / pathology. Lymphoma, Large-Cell, Anaplastic / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Protein Kinase Inhibitors / therapeutic use. Purine-Nucleoside Phosphorylase / antagonists & inhibitors. TNF-Related Apoptosis-Inducing Ligand / antagonists & inhibitors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Surg. 1992 Feb;27(2):230-5 [1564623.001]
  • [Cites] J Clin Oncol. 1989 Jan;7(1):92-9 [2642543.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):383-9 [10667591.001]
  • [Cites] Mol Imaging Biol. 2004 Nov-Dec;6(6):411-6 [15564152.001]
  • [Cites] Pediatr Dev Pathol. 2005 Jan-Feb;8(1):52-60 [15719203.001]
  • [Cites] Blood. 2000 Jan 15;95(2):416-21 [10627444.001]
  • [Cites] Blood. 1996 Jan 15;87(2):423-38 [8555463.001]
  • [Cites] Blood. 1999 Jul 15;94(2):429-33 [10397709.001]
  • [Cites] Ann Oncol. 2000 Jan;11(1):53-8 [10690387.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1430-41 [15846298.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Jan;32(1):31-8 [15605288.001]
  • [Cites] Med Pediatr Oncol. 1975;1(3):235-63 [1232532.001]
  • [Cites] Med Pediatr Oncol. 1992;20(2):105-13 [1734214.001]
  • [Cites] Cancer Surv. 1997;30:59-75 [9547986.001]
  • [Cites] J Clin Pathol. 2003 Mar;56(3):188-92 [12610094.001]
  • [Cites] Cancer Invest. 2004;22(2):304-11 [15199612.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Sep;29(9):1155-65 [12192560.001]
  • [Cites] Am J Clin Pathol. 2004 Apr;121(4):496-506 [15080301.001]
  • [Cites] N Engl J Med. 1996 May 9;334(19):1238-48 [8606720.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]
  • [Cites] J Natl Cancer Inst Monogr. 1998;(23):95-100 [9709310.001]
  • [Cites] J Pediatr. 1994 Dec;125(6 Pt 1):876-85 [7996359.001]
  • [Cites] Curr Med Chem. 2006;13(26):3165-89 [17168705.001]
  • [Cites] Br J Haematol. 2004 May;125(3):414-5 [15086431.001]
  • [Cites] Exp Hematol. 2003 Apr;31(4):309-15 [12691918.001]
  • [Cites] Pediatr Blood Cancer. 2010 Feb;54(2):307-10 [19856388.001]
  • [Cites] Pediatr Blood Cancer. 2005 Nov;45(6):753-69 [15929129.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]
  • [Cites] Med Pediatr Oncol. 2000 Jul;35(1):20-7 [10881003.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1729-35 [9586885.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3535-40 [11325813.001]
  • [Cites] J Clin Oncol. 2000 Nov 15;18(22):3845-53 [11078498.001]
  • [Cites] Eur J Cancer. 2005 Nov;41(16):2485-501 [16243519.001]
  • [Cites] J Pediatr Hematol Oncol. 2009 Dec;31(12):936-41 [19875969.001]
  • [Cites] Ann Nucl Med. 2002 Jul;16(5):337-45 [12230093.001]
  • [Cites] J Clin Invest. 1999 Jul;104(2):155-62 [10411544.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3591-8 [9808552.001]
  • [Cites] JAMA. 2000 Jul 12;284(2):205-9 [10889594.001]
  • [Cites] Leuk Lymphoma. 2005 Oct;46(10):1489-96 [16194895.001]
  • [Cites] Leukemia. 2004 Feb;18(2):238-42 [14628072.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9414-8 [19470474.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4319-27 [11110708.001]
  • [Cites] Am J Hematol. 2003 Jan;72(1):53-63 [12508269.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3371-6 [15161691.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5329-35 [17000665.001]
  • [Cites] J Pediatr Hematol Oncol. 1998 Jul-Aug;20(4):282-96 [9702999.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jan;50(1):37-45 [17420992.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1283-91 [12973853.001]
  • [Cites] N Engl J Med. 1997 Oct 30;337(18):1259-66 [9345074.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):414-9 [11208833.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3699-706 [11389005.001]
  • [Cites] Br J Haematol. 2003 Feb;120(4):660-70 [12588354.001]
  • [Cites] Cancer. 2005 Nov 15;104(10):2133-40 [16211546.001]
  • (PMID = 20640605.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Cysteine Proteinase Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Protein Kinase Inhibitors; 0 / TNF-Related Apoptosis-Inducing Ligand; EC 2.4.2.1 / Purine-Nucleoside Phosphorylase
  •  go-up   go-down


19. Won SC, Han JW, Kwon SY, Shin HY, Ahn HS, Hwang TJ, Yang WI, Lyu CJ: Autologous peripheral blood stem cell transplantation in children with non-Hodgkin's lymphoma: A report from the Korean society of pediatric hematology-oncology. Ann Hematol; 2006 Nov;85(11):787-94
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous peripheral blood stem cell transplantation in children with non-Hodgkin's lymphoma: A report from the Korean society of pediatric hematology-oncology.
  • Recent development of stratified chemotherapeutic regimens has rapidly improved the survival rate of non-Hodgkin's lymphoma (NHL) of childhood.
  • We explored the use of high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (HDC/PBSCT) for children with either refractory or recurrent NHL, and we evaluated various factors influencing outcome of HDC/PBSCT.
  • Sex, stage at diagnosis, histologic subtype (lymphoblastic, Burkitt's, and large-cell lymphoma), LDH level at diagnosis, disease status at transplantation, and preparative regimens for HDC/PBSCT were explored.
  • In regard to the patients, six had Burkitt's lymphoma, 13 had lymphoblastic lymphoma, and 14 had large-cell lymphoma.
  • The EFS for Burkitt's, lymphoblastic, and large-cell lymphoma was 66.7+/-27.2, 50.5+/-14.8, and 82.1+/-11.7%, respectively.
  • In comparison with lymphoblastic and non-lymphoblastic lymphoma, the relative risk for lymphoblastic lymphoma was higher than the others (P = 0.037).
  • EFS between anaplastic large-cell and diffuse large-cell lymphoma was 100 and 55.6+/-24.9%, respectively (P = 0.106).
  • HDC/PBSCT is considered applicable to recurrent or refractory pediatric NHL patients safely and it could replace conventional chemotherapy.
  • In this study, children with CR status at the time of HDC/PBSCT showed higher survival rate.
  • However, refractory or recurrent lymphoblastic lymphoma patients showed dismal results.
  • Therefore, new therapeutic modalities may be needed for this group of NHL patients.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Korea. Male. Retrospective Studies. Salvage Therapy. Survival. Survival Analysis. Transplantation, Autologous. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ann Hematol. 2007 Apr;86(4):309
  • (PMID = 16932891.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


20. Krous HF, Breisch E, Chadwick AE, Pinckney L, Malicki DM, Benador N: Nephrogenic systemic fibrosis with multiorgan involvement in a teenage male after lymphoma, Ewing's sarcoma, end-stage renal disease, and hemodialysis. Pediatr Dev Pathol; 2007 Sep-Oct;10(5):395-402
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nephrogenic systemic fibrosis with multiorgan involvement in a teenage male after lymphoma, Ewing's sarcoma, end-stage renal disease, and hemodialysis.
  • We report a 15-year-old male who developed NSF with multiorgan involvement after successful treatment of renal lymphoma and a subsequent sacral Ewing's sarcoma, and end-stage renal disease treated with hemodialysis.
  • [MeSH-major] Kidney Failure, Chronic / complications. Lymphoma, Large B-Cell, Diffuse / pathology. Renal Dialysis. Sarcoma, Ewing / pathology. Skin Diseases / etiology
  • [MeSH-minor] Adolescent. Antineoplastic Agents / adverse effects. Bone and Bones / pathology. Calcinosis / etiology. Calcinosis / pathology. Dura Mater / pathology. Fibrosis. Humans. Kidney Neoplasms / drug therapy. Kidney Neoplasms / radiotherapy. Kidney Transplantation. Lung Diseases / etiology. Lung Diseases / pathology. Male. Metaplasia. Mitral Valve / pathology. Neoplasms, Second Primary / pathology. Radiotherapy / adverse effects

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • Genetic Alliance. consumer health - Nephrogenic Systemic Fibrosis.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17929984.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


21. Matsubara K, Tanaka T, Taki T, Nakagawa A, Nigami H, Tamura A, Fukaya T: [ATIC-ALK-positive anaplastic large cell lymphoma: a case report and review of the literature]. Rinsho Ketsueki; 2008 May;49(5):325-30
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [ATIC-ALK-positive anaplastic large cell lymphoma: a case report and review of the literature].
  • We report a 10-year-old girl with ATIC-anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL).
  • Radiological and clinical findings indicated Ann Arbor stage IIIA.
  • The patient was assigned to the standard risk group proposed by the international multicenter study for pediatric ALCL, ALCL99.
  • The patient responded well to the treatment and remained in complete remission for more than 26 months.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / genetics. Lymphoma, Large-Cell, Anaplastic / therapy. Oncogene Proteins, Fusion / analysis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Child. Drug Administration Schedule. Female. Humans. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18572809.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / ATIC-ALK fusion protein, human; 0 / Oncogene Proteins, Fusion
  • [Number-of-references] 18
  •  go-up   go-down


22. Küpeli S, Varan A, Demir H, Aydin B, Yüce A, Büyükpamukçu M: Association of Helicobacter pylori and childhood lymphoma. J Pediatr Hematol Oncol; 2007 May;29(5):301-4
MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of Helicobacter pylori and childhood lymphoma.
  • We aimed to estimate the frequency of association between non-Hodgkin lymphoma (NHL) with abdominal, gastric, or intestinal involvement and Helicobacter pylori in childhood.
  • Between February 2003 and June 2006, we evaluated 15 children with newly diagnosed NHL who were diagnosed and treated at the Pediatric Oncology Department of Hacettepe University.
  • Patients who were given chemotherapy previously or who received H. pylori eradication therapy were excluded from the study.
  • Six had stage IV characteristics, whereas another 9 patients had stage III disease.
  • Ten had high-grade B-cell lymphoma.
  • First patient had T-cell lymphoma and stage IV disease with involvement in stomach, mediastinum, peripheral lymph nodes, and bone marrow.
  • The second one had anaplastic large cell lymphoma exclusively in abdominal lymph nodes.
  • Last patient had Burkitt lymphoma and stage IV disease, with primary tumor localization in abdominal lymph nodes, liver, and kidneys.
  • Preliminary results of our study suggest that H. pylori may not be the responsible agent for NHL involved the abdomen in childhood.
  • [MeSH-major] Gastrointestinal Neoplasms / epidemiology. Helicobacter Infections / epidemiology. Helicobacter pylori / isolation & purification. Lymphoma, B-Cell / epidemiology. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adolescent. Anti-Bacterial Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Drug Therapy, Combination. Female. Humans. Male. Neoplasm Staging. Prospective Studies. Recurrence. Risk Assessment. Sampling Studies. Treatment Outcome. Turkey / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17483706.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


23. Ahmad N, Zaidi A, Badar F, Maaz AU, Akram MS: Clinical characteristics and outcome analysis of pediatric B-cell non-Hodgkin's lymphoma. Experience with FAB-LMB 96 and UKCCSG B-cell NHL guidelines in a developing country. Asia Pac J Clin Oncol; 2010 Mar;6(1):49-56

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and outcome analysis of pediatric B-cell non-Hodgkin's lymphoma. Experience with FAB-LMB 96 and UKCCSG B-cell NHL guidelines in a developing country.
  • AIM: To analyze the clinical characteristics of B-cell non-Hodgkin's lymphoma (NHL) patients and the therapeutic efficacy of French-American-British Lymphoma Malins de Burkitt 96 and the recent United Kingdom Children's Cancer Study Group B-cell NHL guidelines in the tertiary care hospital of a developing country.
  • METHODS: Patients aged < or =18 years registered at our hospital between January 1995 and December 2006 with histologically proved B-Cell NHL were selected for retrospective analysis.
  • Of these 95 had Burkitt's lymphoma, 22 diffuse large B-cell lymphoma and five had B-cell NHL not otherwise specified.
  • A total of 37 had uric acid >10 mg/dl and 55 had a lactate dehydrogenase level >500; 73 had stage III and 31 had stage IV while only four presented at stage I and 14 at stage II.
  • All deaths occurred within an average of 35 days from starting treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / mortality. Practice Guidelines as Topic
  • [MeSH-minor] Child. Developing Countries. Female. Humans. Male. Neoplasm Staging. Pakistan. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20398038.001).
  • [ISSN] 1743-7563
  • [Journal-full-title] Asia-Pacific journal of clinical oncology
  • [ISO-abbreviation] Asia Pac J Clin Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


24. Fadoo Z, Belgaumi A, Alam M, Azam I, Naqvi A: Pediatric lymphoma: a 10-year experience at a tertiary care hospital in Pakistan. J Pediatr Hematol Oncol; 2010 Jan;32(1):e14-8
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric lymphoma: a 10-year experience at a tertiary care hospital in Pakistan.
  • SUMMARY: Lymphoma is the third most common childhood malignancy.
  • A retrospective study was carried out at Aga Khan University Hospital, Karachi on children (<15 y) diagnosed with lymphoma from 1998 to 2007.
  • Fifty-one children were diagnosed as non-Hodgkin lymphoma (NHL).
  • Most common histopathologic subtype of NHL was Burkitt lymphoma (55%).
  • Abdominal mass was the main presenting feature of Burkitt and diffuse large B cell lymphoma.
  • T-lymphoblastic lymphoma presented mainly as mediastinal mass.
  • Ten children died, 4 secondary to tumor lysis syndrome, 5 because of disease progression, and 1 with chemotherapy-induced toxicity.
  • One-third of the patients left without treatment.
  • Seventeen children were diagnosed as Hodgkin lymphoma with mixed cellularity as the commonest subtype (65%).
  • Overall survival of children with NHL and Hodgkin lymphoma was 62% and 94%, respectively.
  • A greater proportion of NHL, advanced stage, and profound male preponderance were observed.
  • [MeSH-major] Lymphoma / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20051771.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Eldar AH, Futerman B, Abrahami G, Attias D, Barak AB, Burstein Y, Dvir R, Gabriel H, Horovitz J, Kapelushnik J, Kaplinsky H, Miskin H, Sthoeger D, Toren A, Vilk-Revel S, Weintraub M, Yaniv I, Linn S, Arush MB: Burkitt lymphoma in children: the Israeli experience. J Pediatr Hematol Oncol; 2009 Jun;31(6):428-36

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma in children: the Israeli experience.
  • BACKGROUND: We analyzed the results of the French-American-British-LMB 96 protocol performed in 9 centers in Israel on 88 patients with B-cell non-Hodgkin lymphoma treated from 2000 to 2005.
  • PROCEDURE: The majority of the patients was male (63/88, 72%), with a median age of 8.9 years (range, 2.5 to 20 y).
  • Fifty (57%) patients were classified as Burkitt lymphoma, 5 (5.7%) as Burkitt-like lymphoma, 22 (25%) as diffuse large B cell (DLBC), and 9 (10.2%) as Burkitt leukemia with over 25% of their bone marrow (BM) involved.
  • Stage I: 9.1%; stage II: 28.4%; stage III: 45.5%, stage IV: 17%.
  • RESULTS: With a median follow-up of 3 years (12 mo to 7.6 y), the Kaplan-Meier for event-free survival (EFS) and overall survival (OS) according to whole group treatment was 88.6% and 90.9%, group A was 100% and 100%; group B was 89.9% and 92.8%; and group C was 78.6% and 78.6%.
  • CONCLUSIONS: In nonresected mature B-cell lymphoma of childhood and adolescence with no BM or CNS involvement, a 93% cure rate can be achieved, similar to the French-American-British/LMB 96 trial.
  • Patients with primary DLBC mediastinal mass had a significantly reduced OS, indicating the need for a different therapeutic approach.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / mortality
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Israel. Kaplan-Meier Estimate. Male. Neoplasm Recurrence, Local / pathology. Randomized Controlled Trials as Topic. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19648792.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


26. Glotzbecker MP, Kersun LS, Choi JK, Wills BP, Schaffer AA, Dormans JP: Primary non-Hodgkin's lymphoma of bone in children. J Bone Joint Surg Am; 2006 Mar;88(3):583-94
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of bone in children.
  • BACKGROUND: Primary non-Hodgkin's lymphoma of bone, often more simply referred to as primary lymphoma of bone, is a rare subset of non-Hodgkin's lymphoma in children.
  • There are only a few small series of primary lymphoma of bone in children with long-term follow-up, and none have appeared in the orthopaedic literature.
  • METHODS: A review of our institution's Pediatric Tumor Registry identified fifteen cases of primary lymphoma of bone among 306 cases of diagnosed non-Hodgkin's lymphoma between 1970 and 2003.
  • Retrospective evaluation included collection of demographic, clinical, radiographic, treatment, and follow-up data.
  • Five patients died: three of disease progression, one of treatment-related complications, and one of an unrelated cause.
  • The mean time from diagnosis to death was 2.1 years.
  • Nine patients received chemotherapy only, whereas six patients received a combination of chemotherapy and radiation therapy.
  • In the summary analysis of cases collected from the literature, advanced stage, young age, non-large-cell histology, and multiple-bone involvement were predictive of poor survival (p < 0.05).
  • CONCLUSIONS: On the basis of the present series and a comprehensive review of similar series in the literature involving patients with primary lymphoma of bone, it appears that younger age, advanced-stage disease, multiple-bone involvement, and non-large-cell histology are associated with decreased survival as compared with older age, localized disease, single-bone involvement, and large-cell histology, respectively.
  • [MeSH-major] Bone Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16510826.001).
  • [ISSN] 0021-9355
  • [Journal-full-title] The Journal of bone and joint surgery. American volume
  • [ISO-abbreviation] J Bone Joint Surg Am
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Morgan E, Pahl E: Early heart transplant in a child with advanced lymphoma. Pediatr Transplant; 2002 Dec;6(6):509-12
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early heart transplant in a child with advanced lymphoma.
  • A child with advanced stage large cell lymphoma in remission developed overwhelming, irreversible anthracycline cardiac toxicity incompatible with life early in her treatment course.
  • The medical complexities and ethical issues concerning a decision to proceed with orthotopic heart transplantation are discussed.
  • [MeSH-major] Antibiotics, Antineoplastic / adverse effects. Antineoplastic Agents / adverse effects. Doxorubicin / adverse effects. Heart Diseases / chemically induced. Heart Transplantation. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Child. Female. Heart / drug effects. Humans


28. Attarbaschi A, Dworzak M, Steiner M, Urban C, Fink FM, Reiter A, Gadner H, Mann G: Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: a population-based analysis of the Austrian Cooperative Study Group. Pediatr Blood Cancer; 2005 Jan;44(1):70-6
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: a population-based analysis of the Austrian Cooperative Study Group.
  • BACKGROUND: Children and adolescents with Non-Hodgkin lymphoma (NHL) and mature B-cell leukemia (B-ALL) have an excellent prognosis with contemporary chemotherapy stratified according to the histologic subtype and clinical stage of disease.
  • However, a small subset of patients does not respond to front-line therapy or suffers from an early relapse.
  • PROCEDURE: A retrospective analysis was performed to assess the incidence, treatment, and outcome of all children with relapsed or progressed NHL and B-ALL diagnosed in Austria between 1986 and 2003 (n = 22/234).
  • RESULTS: Nine of 140 (6.5%) patients with B-cell NHL/B-ALL (relapse, n = 6; progress, n = 3) failed initial treatment.
  • Four of them underwent a hematopoietic stem cell transplantation (HSCT) as second-line therapy, two patients received intensive chemotherapy alone and in three patients treatment was palliative.
  • Four of 65 (6%) patients with lymphoblastic lymphoma (LBL) (relapse, n = 2; progress, n = 2) had a treatment failure.
  • High-dose chemotherapy followed by HSCT was performed in two of the four patients; another two patients received chemotherapy alone.
  • Nine of 29 (31%) patients with anaplastic large cell lymphoma (ALCL) (relapse, n = 7; progress, n = 2) failed first-line therapy.
  • Treatment of the other three patients consisted of chemotherapy alone-they all died of tumor progression.
  • CONCLUSIONS: Conclusively, patients with early relapsed and progressive B-cell neoplasia or LBL have a very poor prognosis with current treatment approaches, while those with ALCL have a respectable chance to achieve a sustained complete second remission with high-dose chemotherapy and HSCT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease Progression. Drug Resistance, Neoplasm. Female. Humans. Infant. Male. Prognosis. Recurrence. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15368550.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


29. Klumb CE, Schramm MT, De Resende LM, Carriço MK, Coelho AM, de Meis E, Ferreira RM, Maia RC, Dobbin Jde A: Treatment of children with B-cell non-Hodgkin's lymphoma in developing countries: the experience of a single center in Brazil. J Pediatr Hematol Oncol; 2004 Jul;26(7):462-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of children with B-cell non-Hodgkin's lymphoma in developing countries: the experience of a single center in Brazil.
  • PURPOSE: To treat non-Hodgkin's B-cell lymphoma (B-NHL) in children with manageable toxicity-related morbidity and without any decrease in survival.
  • The patients were stratified by risk factors (stage and LDH level) and treated with a BFM 86/90 (Berlin-Frankfurt-Münster)-based protocol with reduction of the methotrexate dose from 5 mg/m to 2 mg/m.
  • Seventy-two percent of the patients had lymphomas classified as Burkitt type, 11% as diffuse large cell lymphoma, and 6% as Burkitt-like lymphoma, and 11% were not classified.
  • The event-free survival rate for all patients was 78% (SE = 0.07): 100% (SE = 0.0) for stage I/II patients and 74% (SE = 0.08) for stage III/IV patients.
  • Six patients suffered initial treatment failure and one patient relapsed, all of whom died.
  • There was only one death from sepsis related to treatment.
  • The results were comparable to those of the BFM 90 study and other contemporary groups and represented an increase in the cure rates in childhood B-NHL in Brazil.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asparaginase / therapeutic use. Daunorubicin / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / mortality. Prednisone / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Adolescent. Brazil. Child. Child, Preschool. Female. Humans. Infant. Male. Neoplasm Staging. Risk Factors. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15218425.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


30. Sposto R, Meadows AT, Chilcote RR, Steinherz PG, Kjeldsberg C, Kadin ME, Krailo MD, Termuhlen AM, Morse M, Siegel SE: Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin-COMP: A report from the Children's Cancer Group. Med Pediatr Oncol; 2001 Nov;37(5):432-41
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin-COMP: A report from the Children's Cancer Group.
  • BACKGROUND: Early Children's Cancer Group (CCG) trials indicated that the cyclophosphamide, vincristine, methotrexate, and prednisone (COMP) regimen was superior to the LSA2L2 regimen for non-lymphoblastic (NLB) non-Hodgkin lymphoma (NHL).
  • Studies by other groups suggested that addition of anthracyclines to standard therapies could improve outcome.
  • Patients with CNS or marrow involvement (stage IV) were non-randomly treated with D-COMP (N = 120).
  • RESULTS: Ten-year event-free survival in COMP and D-COMP patients was similar: 55 +/- 4.3% (Estimate +/- SE) vs. 57 +/- 4.2% (not significant).
  • Stage I-III patients with large-cell (LC) NHL had worse 10-year event-free survival (EFS) (48 +/- 4.9%) than those with small non-cleaved cell (SNCC) NHL disease (61 +/- 3.5%, P < 0.05 in multivariate analysis), but equivalent survival (65 +/- 4.7% vs. 63 +/- 3.5%) due to significantly higher salvage rates in LC patients, especially those failing more than 12 months from diagnosis.
  • Ten-year EFS in stage IV patients was 39 +/- 5.2%.
  • CONCLUSIONS: Addition of daunomycin to standard COMP therapy did not improve outcome in pediatric disseminated NLB NHL.
  • [MeSH-major] Antibiotics, Antineoplastic / pharmacology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Daunorubicin / pharmacology. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Female. Follow-Up Studies. Heart Diseases / chemically induced. Humans. Infant. Infant, Newborn. Infusions, Intravenous. Male. Methotrexate / administration & dosage. Neutropenia / chemically induced. Prednisone / administration & dosage. Recurrence. Stomatitis / chemically induced. Survival Analysis. Thrombocytopenia / chemically induced. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11745871.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 02649; United States / NCI NIH HHS / CA / CA 02971; United States / NCI NIH HHS / CA / CA 03526; United States / NCI NIH HHS / CA / CA 03750; United States / NCI NIH HHS / CA / CA 03888; United States / NCI NIH HHS / CA / CA 07306; United States / NCI NIH HHS / CA / CA 07431; United States / NCI NIH HHS / CA / CA 10382; United States / NCI NIH HHS / CA / CA 11796; United States / NCI NIH HHS / CA / CA 13539; United States / NCI NIH HHS / CA / CA 14560; United States / NCI NIH HHS / CA / CA 17829; United States / NCI NIH HHS / CA / CA 20320; United States / NCI NIH HHS / CA / CA 26044; United States / NCI NIH HHS / CA / CA 26126; United States / NCI NIH HHS / CA / CA 26270; United States / NCI NIH HHS / CA / CA 27678; United States / NCI NIH HHS / CA / CA 28851; United States / NCI NIH HHS / CA / CA 28882; United States / NCI NIH HHS / CA / CA 29013; United States / NCI NIH HHS / CA / CA 29314; United States / NCI NIH HHS / CA / CA 36004; United States / NCI NIH HHS / CA / CA 36015
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; COMP protocol
  •  go-up   go-down


31. Yang CP, Hung JJ, Jaing TH, Lin KH, Lin DT, Lu MY, Liang DC, Chen SH, Liu HC, Hsiao CC, Shu SG, Chen JS, Chang TT, Chiou SS, Hsieh YL, Lin MT, Lee MT, Peng CT, Cheng SN, Chen RL, Chen BW, Lin KS: Treatment results of the TPOG-NHL92 protocols for childhood non-Hodgkin's lymphomas in Taiwan: a report from the Taiwan Pediatric Oncology Group (TPOG). Acta Paediatr Taiwan; 2000 Jul-Aug;41(4):193-204

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results of the TPOG-NHL92 protocols for childhood non-Hodgkin's lymphomas in Taiwan: a report from the Taiwan Pediatric Oncology Group (TPOG)
  • A nation-wide chemotherapeutic trial for childhood non-Hodgkin's lymphoma (NHL) was conducted by the Taiwan Pediatric Oncology Group (TPOG).
  • Four TPOG-NHL92 protocols based on stage and histology were activated in 1992: TPOG-92LD (treatment duration: 8 months) was used for localized (stages I/II) NHL with any histology, 92LB (2 years), 92SNC (5 months), and 92LC (1 year) for advanced (stages III/IV) lymphoblastic (LB), small non-cleaved cell (SNC), and large cell (LC) lymphoma, respectively.
  • There were 54 (27.3%) patients with LB, 94 (47.5%) with SNC including B-cell acute lymphoblastic leukemia (B-ALL), and 50 (25.2%) with LC.
  • There were 176 patients eligible for evaluation of treatment results.
  • As of August 31, 1999, 26 patients relapsed, six died during remission, one patient developed secondary acute myelomonocytic leukemia, and 105 patients remained in continuous remission with a median remission duration of 49 months.
  • We concluded that following the strategy of stratification of therapy, only disease stages had prognostic significance in this study.
  • More efforts are needed to improve our treatment results.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Paediatr Taiwan. 2000 Jul-Aug;41(4):175-6 [11021000.001]
  • (PMID = 11021005.001).
  • [ISSN] 1608-8115
  • [Journal-full-title] Acta paediatrica Taiwanica = Taiwan er ke yi xue hui za zhi
  • [ISO-abbreviation] Acta Paediatr Taiwan
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


32. Halperin EC, Laurie F, Fitzgerald TJ: An evaluation of the relationship between the quality of prophylactic cranial radiotherapy in childhood acute leukemia and institutional experience: a Quality Assurance Review Center-Pediatric Oncology Group study. Int J Radiat Oncol Biol Phys; 2002 Jul 15;53(4):1001-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An evaluation of the relationship between the quality of prophylactic cranial radiotherapy in childhood acute leukemia and institutional experience: a Quality Assurance Review Center-Pediatric Oncology Group study.
  • PURPOSE: The Pediatric Oncology Group Protocol 9404 was a prospective clinical trial of two forms of chemotherapy in childhood T-cell acute lymphoblastic leukemia and advanced stage T-cell lymphoblastic non-Hodgkin's lymphoma.
  • The protocol called for prophylactic C1 whole brain external beam irradiation, 18 Gy in 2 Gy/fraction for 9 fractions.
  • Treatment volumes were scored as a minor deviation if the margins were less than specified or the fields were excessively large.
  • When the treating physician submitted a treatment plan and simulator film at the initiation of therapy to the Quality Assurance Review Center (QARC), a rapid turn-around review of the plan and suggestions for improvement was provided.
  • At the end of therapy, all simulator and port films were reviewed at the QARC.
  • The frequency of major deviations fell over time (1996-1997, 15.5% vs. 1998-2001, 4.7%, p < 0.001).
  • A trend (p < 0.09) was noted, however, for major deviations to decrease as a function of institutional experience, as well as over time (p < 0.001), supporting the validity of the hypothesis that pediatric clinical experience matters in QA for C1 whole brain leukemia radiotherapy.
  • [MeSH-major] Brain / radiation effects. Clinical Trials as Topic / standards. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy

  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12095569.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10CA15525-29; United States / NCI NIH HHS / CA / CA29511
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


33. Temmim L, Baker H, Amanguno H, Madda JP, Sinowatz F: Clinicopathological features of extranodal lymphomas: Kuwait experience. Oncology; 2004;67(5-6):382-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 935 patients with extranodal non-Hodgkin lymphoma (NHL) diagnosed in the period between January 1985 and December 2000 in Kuwait Cancer Center, serving the whole population of Kuwait, were used to describe the clinicopathological and epidemiological features of extranodal lymphomas in Kuwait.
  • Extranodal lymphomas accounted for 45% of all NHL observed during this time.
  • The most common lymphoma observed was diffuse large B-cell lymphoma (58.60%) followed by Burkitt s lymphoma (BL) (3.80%).
  • In the pediatric group, BL comprises more than two thirds of all patients (77.20%).
  • The most common extranodal sites were stomach (19.70%) and skin (17.80%) in the adult group, large intestine (29.80%) and small intestine (19.30%) in the pediatric age group.
  • The majority (73.40%) of adult extranodal lymphomas was in stage IE-IIE and had a very good prognosis.
  • On the contrary, the majority of pediatric extranodal lymphomas were found to be in stage III and IV.
  • Variations in treatment policies (single agent or combined chemotherapy, radiotherapy, combined modality treatment) adopted and changed during the time period of 16 years of this retrospective study were documented.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / pathology. Child. Child, Preschool. Female. Humans. Infant. Intestinal Neoplasms / epidemiology. Intestinal Neoplasms / pathology. Kuwait / epidemiology. Lymphoma, B-Cell / epidemiology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Registries. Retrospective Studies. Skin Neoplasms / epidemiology. Skin Neoplasms / pathology. Stomach Neoplasms / epidemiology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2004 S. Karger AG, Basel
  • (PMID = 15713994.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


34. Snyder RL: Resumption of high-dose methotrexate after methotrexate-induced nephrotoxicity and carboxypeptidase G2 use. Am J Health Syst Pharm; 2007 Jun 1;64(11):1163-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The successful resumption of high-dose methotrexate in a 13-year-old boy with recurrent anaplastic large-cell lymphoma (ALCL) who suffered renal dysfunction after a 24-hour infusion of high-dose methotrexate and required treatment with carboxypeptidase G(2) (CPDG(2) ) is described.
  • SUMMARY: A 13-year-old boy who had been diagnosed in 2001 with stage I ALCL was admitted to the hospital in February 2005 after he developed a smaller left axillary mass in the area of his original mass.
  • Recurrent ALCL was diagnosed, and treatments were initiated based on branch K3 of the protocol published in the non-Hodgkin's lymphoma-Berlin-Frankfurt-Münster (NHL-BFM) trial 90.
  • In the NHL-BFM 90 protocol, all AA and BB courses include high-dose methotrexate therapy, which consists of aggressive alkalinized hydration, methotrexate 5 g/m(2) given as an i.v. infusion over 24 hours, and leucovorin rescue.
  • Because the patient's elimination of methotrexate remained slow and his serum creatinine level remained above normal limits, CPDG(2) was obtained for the treatment of methotrexate toxicity.
  • He is currently in remission on maintenance therapy.
  • The resultant delayed methotrexate clearance required the standard therapies as well as use of investigational CPDG(2).
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / adverse effects. Methotrexate / administration & dosage. Methotrexate / adverse effects. Renal Insufficiency / drug therapy. gamma-Glutamyl Hydrolase / therapeutic use
  • [MeSH-minor] Adolescent. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Neoplasm Recurrence, Local. Retreatment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17519458.001).
  • [ISSN] 1079-2082
  • [Journal-full-title] American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • [ISO-abbreviation] Am J Health Syst Pharm
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 3.4.19.9 / gamma-Glutamyl Hydrolase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down






Advertisement